5 Ways Emerging Biotech Sponsors Can Achieve Faster IRB Review During Study Start-Up
greenbutterfly | Adobe Stock
“The regulatory climate in the U.S. remains unpredictable, leaving some companies with the kind of surprise rejections and delays that make risky biotech investments even riskier,” notes a recent industry outlook. Emerging biotechs operate in an environment where speed is a baseline expectation, and growing global competition adds pressure to move quickly.
Rapid study and site activation are critical for venture-backed organizations with lean staffing and milestone-driven financing. However, ethical oversight cannot be rushed.
For sponsors advancing novel therapies, understanding Institutional Review Board (IRB) expectations early and anticipating likely questions can prevent avoidable delays. When sponsors and IRBs align early on what a “ready for review” submission entails, start-up moves forward more smoothly without compromising informed consent form quality, risk clarity, or compliance with federal regulations.
1. Start Upstream: Align Before Submitting
Protocol clarity, safety narratives, and constructive supporting materials directly influence the viability of the IRB submission package and, consequently, your study initiation timing.
For emerging biotech sponsors who are often building processes while navigating tight operational restraints, it can be invaluable to have early, collaborative dialogue with an IRB. Proactive engagement can significantly reduce downstream effects such as the need to modify/amend the research proposal and preserve research momentum.
2. Submit a “Review-Ready” Informed Consent Form
The informed consent form (ICF) is one of the most scrutinized documents involved in IRB submission. Patient safety is best protected, and study start-up is kept on track when sponsors develop informed consent forms that clearly communicate the nature of the research, its risks, potential benefits, and what is involved. With a simple, clear form and a robust consent process, research participants are genuinely informed and can make a clear decision. A “review-ready” ICF will include all applicable elements of informed consent as outlined by federal regulations, such as:
- The purpose of the research and a description of what procedures will be involved
- Description of reasonably foreseeable risks or discomforts in alignment with those in the protocol and the investigator brochure (IB).
- Description of potential benefits
- Alternative procedures
Compensation for research-related injury
3. Strengthen the Protocol’s Risk Narrative & Risk-Benefit Rationale
IRBs evaluate whether studies minimize risks relative to the anticipated research benefits. A well-developed risk narrative makes that assessment straightforward. Sponsors should:
- Clearly justify dose selection and escalation strategies.
- Explain risk minimization approaches, including safety monitoring, stopping rules, and staggered enrollment.
Describe how new information will be monitored and communicated.
4. Tailor Protocol Details for IRB-Readiness
As early-phase studies are geared toward evaluating safety and tolerability, they often require more detailed explanations of preclinical findings and risk mitigation.
Additionally, robust operational practices, such as rigorous version control, are important for keeping research protocol development organized, especially in a fast-paced environment where strong compliance and high quality are critical.
TIP: To reduce confusion and administrative effort during submission and response cycles, teams can benefit from standardized templates and document tracking SOPs.
5. Plan for Fast Responses to IRB Questions
The IRB review timeline is shaped not only by the initial submission but also by how quickly and cohesively sponsors respond to questions. Clear expectations on both sides of
the submission lead to smoother approvals.
TIP: To empower prompt, consistent responses to IRB questions, sponsors can establish internal owners for safety, regulatory, and clinical submission components in advance.
Treat IRB Review as a Collaborative Start-Up Milestone
Often, IRB review may be perceived as a “check the box” activity in the overall research plan, but it is a critical and important check and balance in the research process. Investing time upfront to ensure alignment with the IRB review approach saves time.
Ultimately, sponsors and IRBs share the same objective: protecting participants while advancing innovative science. Finding the right IRB partner enables emerging biotech sponsors to minimize study liability, streamline submission turnarounds, and accelerate disease research and personalized medicine discovery.
